Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study

Journal of Rheumatology

Volumn 36, Issue 8, 2009, Pages 1611-1617

  Lee, Susan J ^a,f   Chang, Hong ^b   Yazici, Yusuf ^c   Greenberg, Jeffrey D ^c   Kremer, Joel M ^d,e   Kavanaugh, Arthur ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ALBANY MEDICAL COLLEGE   (United States)

^e Center for Rheumatology LLP   (United States)

^f NONE   (United States)

Author keywords

Rheumatoid arthritis; Treatment; Tumor necrosis factor inhibitor; Utilization

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DEMOGRAPHY; DISEASE ACTIVITY; DRUG UTILIZATION; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; UNITED STATES;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DRUG UTILIZATION; FEMALE; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 68849125759     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080889     Document Type: Article

References (25)

1. Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989;16:585-91.
2. van der Heijde DM, van Leeuwen MA, van Riel PL, van de Putte LB. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol 1995;22:1792-6.
3. Breedveld FC, Emery P, Keystone E, et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004;63:149-55.
4. St. Clair EW, van der Heijde DMFM, Smolen JS, et al, for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. Arthritis Rheum 2004;50:3432-43.
5. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
6. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis. Arthritis Rheum 2002;46:1443-50.
7. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
8. Cush JJ. Biological drug use: US perspectives on indications and monitoring. Ann Rheum Dis 2005;64 Suppl:iv18-23.
9. Saag K, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84.
10. Jordan JM. Effect of race and ethnicity on outcomes in arthritis and rheumatic conditions. Curr Opin Rheumatol 1999;11:98-103.
11. Callahan LF, Pincus T. Formal education level as a significant marker of clinical status in rheumatoid arthritis. Arth Rheum 1988;31:1346-57.
12. Criswell LA, Katz PP. Relationship of education level to treatment received for rheumatoid arthritis. J Rheumatol 1994;21:11:2026-33.
13. Groessl EJ, Ganiats TG, Sarkin AJ. Sociodemographic differences in quality of life in rheumatoid arthritis. Pharmacoeconomics 2006:24:109-21.
14. Brunner HI, Taylor J, Britto MT, et al. Differences in disease outcomes between Medicaid and privately insured children: possible health disparity in juvenile rheumatoid arthritis. Arthritis Rheum 2006;55:378-84.
15. Kremer JM, Gibofsky A, Greenberg J. The role of drug and disease registries in rheumatic disease epidemiology. Curr Opin Rheumatol 2008;20:12-30.
16. Breedveld FC, Emery P, Keystone E, et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004;63:149-55.
17. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
18. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis. Arthritis Rheum 2002;46:1443-50.
19. Breedveld F, Weisman M, Kavanaugh A, et al. Adalimumab plus methotrexate versus methotrexate or adalimumab alone in methotrexate-naïve patients with early aggressive rheumatoid arthritis: results of the PREMIER study. Arthritis Rheum 2006;54:26-37.
20. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
21. Keystone E, Kavanaugh AF, Fischkof S. Response to adalimumab in patients with early versus late rheumatoid arthritis (RA). Ann Rheum Dis 2003;62 Suppl:170.
22. Lipsky PE, van der Heijde DMFM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. New Engl J Med 2000;343:1594-602.
23. Kobelt G, Eberhardt K, Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 2004;63:4-10.
24. Chen YF, Jobanputra P, Barton P, et al. A systemic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:iii-iv, xi-xiii, 1-229.
25. Sorensen J, Andersen LS. The case of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis: a budget impact analysis. Pharmacoeconomics 2005;23:289-98.